Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Branded Generics Market Through 2029?

The market size for branded generics has seen significant growth in the past few years. Its expansion is projected to continue, rising from $363.49 billion in 2024 to $393.5 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.3%. Factors driving the growth during the historical period include affordability and cost savings, the expiration of patents, market outreach and expansion, government strategies and policies, as well as healthcare reforms.

It is anticipated that the branded generics market will experience swift expansion in the upcoming years. The projected growth suggests that the value will escalate to “$588.37 billion in 2029, with a compound annual growth rate (CAGR) of 10.6%.” This predicted acceleration during the forecast period can be attributed to the increased demand for generic biologics along with the surge in chronic diseases, burgeoning markets, and emphasis on biosimilars. The future trends observed include strategic alliances, technological evolutions, concentration on chronic ailments, consolidation of the market, and a patient-centric approach.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Market Forces Are Driving The Branded Generics Sector In 2025 And Beyond?

The rising incidence of chronic diseases are projected to fuel the expansion of the branded generics market. Chronic diseases, often incurable yet manageable, are persistent in nature. Increasing tobacco consumption, inadequate nutrition, lack of physical activity, and excessive alcohol intake are some factors contributing to the rise of chronic diseases. Globally, consumers prefer branded generics for treating chronic diseases due to their lower price compared to conventional medications. For example, in September 2022, the World Health Organization (WHO) 2022 Highlights reported that 74% of all deaths worldwide, equating to 41 million fatalities, resulted from noncommunicable diseases (NCDs) or chronic diseases. This upsurge in chronic diseases is anticipated to drive the demand for branded generics in the forecast period.

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Which Trends Are Redefining The Future Landscape Of The Branded Generics Industry?

Strategic alliances are a significant trend in the branded generics market. Firms in the branded generics domain are forming partnerships with corresponding companies to utilize their resources mutually and penetrate new markets. E.g., Biocon Ltd., an Indian pharmaceutical firm, collaborated with Tabuk Pharmaceuticals in September 2024. Biocon will undertake the development and production of GLP-1 items, guaranteeing top-tier biopharmaceuticals designed specifically for diabetes care. Tabuk Pharmaceuticals, on the other hand, will have marketing authorization and will oversee the registration, importation, and promotion of these products predominantly in Saudi Arabia. The agreement also comprises stipulations for further expansion into other GLP products beyond the initial offerings, enabling a wider spectrum of diabetes therapies. This collaboration is designed to deliver bespoke health solutions that elevate the health of patients in Saudi Arabia and nearby regions, complementing both firms’ devotion to augmenting healthcare accessibility. Based in Saudi Arabia, Tabuk Pharmaceuticals commercializes branded and generic pharmaceutical goods.

Which Firms Are Considered Leaders In The Branded Generics Market Space?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

What Role Do Regional Policies And Investments Play In Branded Generics Market Expansion?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model